# US 2022/0031769 A1 · Strain for preventing and treating metabolic diseases and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031769 A1
- Document ID: US20220031769A1
- Status: Published application
- Kind: A1
- Application number: 17/278,662
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-27
- Assignees: Sph Sine Pharmaceutical Laboratories Co., Ltd; Shanghai Institute of Endocrine and Metabolic Diseases
- Applicants: Sph Sine Pharmaceutical Laboratories Co., Ltd; Shanghai Institute of Endocrine and Metabolic Diseases
- Inventors: Bin WEN; Guang NING; Xin MA; Weiqing WANG; Hongjing YU; Jie HONG; Ningyun SUN; Jiqiu WANG; Peijun YIN; Ruixin LIU; Yuan GAO; Shasha WANG
- Web page: https://patentgrep.com/patent/US20220031769A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 1/205: Bacterial isolates
- A61K 2035/115: {Probiotics}
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Provided are an Akkermansia muciniphila strain and use thereof in preventing and treating metabolic diseases. This strain is named Akkermansia muciniphila SSYD-3 and the accession number thereof is CGMCC No. 14764. This strain is more ideal than the existing Ackermannia strain ATCC BAA835 in respect of fermentation performance, storage stability, acid and bile resistance, and the effect on treating metabolic diseases.

## Claims

### Claim 1

A preparation comprising a strain for preventing and treating metabolic diseases, wherein the strain is Akkermansia muciniphila strain, which is named Akkermansia muciniphila SSYD-3 with accession number of CGMCC No. 14764 for the deposit.

### Claim 2 (depends on 1)

A method for preventing and treating metabolic diseases in a subject in need thereof, comprising: administering the preparation of claim 1 to the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the preparation is prepared by using an effective dose of the Akkermansia muciniphila strain as an active ingredient and adding with pharmaceutical excipients.

### Claim 4 (depends on 2)

The method of claim 2, wherein the preparation is a lyophilized bacterial inoculum, which has a count of 1010 CFU/g viable bacteria of the Akkermansia muciniphila strain.

### Claim 5 (depends on 3)

The method of claim 3, wherein the effective dose means that Akkermansia muciniphila, as the main active ingredient in a solid viable bacterial preparation, has a viable count of 106-1014 CFU/g.

### Claim 6 (depends on 3)

The method of claim 3, wherein the effective dose means that Akkermansia muciniphila, as the main active ingredient in a liquid viable bacterial preparation, has a viable count of 106-1014 CFU/g.

### Claim 7 (depends on 2)

The method of claim 2, wherein the metabolic diseases are selected from one or more of the following diseases: preventing and treating obesity, type 2 diabetes and metabolism syndrome, and other diseases that combine weight gain and glucose metabolism disorders.

### Claim 8 (depends on 2)

The method of claim 2, wherein administration of the preparation comprises one or more of the following functions: delaying weight gain, reducing visceral adipose tissue, reducing blood-glucose 15 min˜30 min after glucose injection, and reducing fasting blood-glucose and blood blood-glucose within 60 minutes after insulin injection.

### Claim 9

A method for preventing and treating metabolic diseases in a subject in need thereof, comprising: administering an effective dose of a strain to the subject, wherein the strain is Akkermansia muciniphila SSYD-3 with accession number of CGMCC No. 14764 for the deposit.

### Claim 10 (depends on 9)

The method of claim 9, wherein the effective dose means that Akkermansia muciniphila has a viable count of 106-1014 CFU/g.

### Claim 11 (depends on 9)

The method of claim 9, wherein the metabolic diseases are selected from one or more of the following diseases: preventing and treating obesity, type 2 diabetes and metabolism syndrome, and other diseases that combine weight gain and glucose metabolism disorders.

### Claim 12 (depends on 9)

The method of claim 9, wherein administration of the preparation comprises one or more of the following functions: delaying weight gain, reducing visceral adipose tissue, reducing blood-glucose 15 min˜30 min after glucose injection, and reducing fasting blood-glucose and blood blood-glucose within 60 minutes after insulin injection.

### Claim 13 (depends on 1)

The preparation of claim 1, wherein the preparation is a lyophilized bacterial inoculum, which has a count of 106-1014 CFU/g viable bacteria of the Akkermansia muciniphila strain.

### Claim 14 (depends on 13)

The preparation of claim 13, wherein the lyophilized bacterial inoculum has a count of 1010 CFU/g viable bacteria of the Akkermansia muciniphila strain.

### Claim 15 (depends on 13)

The preparation of claim 13, wherein the preparation further comprises lyophilized protectant which comprises trehalose, sucrose and milk powder.

### Claim 16 (depends on 15)

The preparation of claim 15, wherein the trehalose, sucrose and milk powder has a mass percentage of 5%, 5% and 10% respectively in the solution before lyophilization.

### Claim 17

A strain composition comprising a strain and a mixture, wherein the strain is Akkermansia muciniphila strain, which is named Akkermansia muciniphila SSYD-3 with accession number of CGMCC No. 14764 for the deposit.

### Claim 18 (depends on 17)

The strain composition of claim 17, wherein the mixture is a Brain Heart Infusion Broth or a culture medium comprising 5 g tryptone, 5 g soybean peptone, 5 g beef powder, 5 g yeast powder, 4 g glucose, 3gNaCl, 1.5 g MgSO4, Na2HPO4, KH2PO4 and 1 L water with a pH of 7.2.

### Claim 19 (depends on 17)

The strain composition of claim 17, wherein the mixture is prepared by dissolving 2.0 sodium chloride and 3.2 g pepsin in 7.0 ml hydrochloric acid and water, and replenished to 1000 mL with water.

### Claim 20 (depends on 17)

The strain composition of claim 17, wherein the mixture is prepared by mixing solution 1 and solution 2, and replenished to 1000 mL with water, wherein:
(1) the solution 1 is prepared by adding potassium dihydrogen phosphate and 3 g of bile salt No. 3 into 500 mL of water, followed by adjusting the pH to 6.8 with 0.4% sodium hydroxide solution;
(2) the solution 2 is prepared by dissolving 10 g of pancreatin in appropriate amount of water.
